Saturday, May, 25, 2019 08:15:23

Category: Health

FDA panel split over Lexicon-Sanofi diabetes drug Sotagliflozin

Not all 1.3 million American adults with type-1 diabetes will be eligible to receive Sotagliflozin. The U.S. Food and Drug Administration (FDA) advisory panel, was reportedly divided over whether to recommend the approval for a type-1 diabetes treatment developed by biopharmaceutical firms – Lexicon Pharmaceuticals …